215 related articles for article (PubMed ID: 36485104)
21. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
[TBL] [Abstract][Full Text] [Related]
22. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
Budde LE; Guthrie KA; Till BG; Press OW; Chauncey TR; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Maloney DG; Gopal AK
J Clin Oncol; 2011 Aug; 29(22):3023-9. PubMed ID: 21730271
[TBL] [Abstract][Full Text] [Related]
23. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
[TBL] [Abstract][Full Text] [Related]
24. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
[TBL] [Abstract][Full Text] [Related]
25. Controversies in the treatment of lymphoma with autologous transplantation.
Moskowitz AJ; Moskowitz CH
Oncologist; 2009 Sep; 14(9):921-9. PubMed ID: 19737999
[TBL] [Abstract][Full Text] [Related]
26. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Ng ZY; Bishton M; Ritchie D; Campbell R; Gilbertson M; Hill K; Ratnasingam S; Schwarer A; Manos K; Shorten S; Ng M; Nelson N; Xin L; De Mel Widanalage S; Sunny T; Purtill D; Poon M; Johnston A; Cochrane T; Lee HP; Hapgood G; Tam C; Opat S; Hawkes E; Seymour J; Cheah CY
Hematol Oncol; 2019 Aug; 37(3):253-260. PubMed ID: 30983008
[TBL] [Abstract][Full Text] [Related]
27. Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era.
Mathys A; Bacher U; Banz Y; Legros M; Mansouri Taleghani B; Novak U; Pabst T
Hematol Oncol; 2022 Apr; 40(2):292-296. PubMed ID: 34817087
[TBL] [Abstract][Full Text] [Related]
28. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
29. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Villa D; Hoster E; Hermine O; Klapper W; Szymczyk M; Bosly A; Unterhalt M; Rimsza LM; Ramsower CA; Freeman CL; Scott DW; Gerrie AS; Savage KJ; Sehn LH; Dreyling M
Blood Adv; 2022 Sep; 6(18):5285-5294. PubMed ID: 35439293
[TBL] [Abstract][Full Text] [Related]
30. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
Metzner B; Müller TH; Casper J; Kimmich C; Köhne CH; Petershofen E; Renzelmann A; Thole R; Voss A; Dreyling M; Hoster E; Klapper W; Pott C
Eur J Haematol; 2023 Aug; 111(2):220-228. PubMed ID: 37094812
[TBL] [Abstract][Full Text] [Related]
32. Up-Front ASCT Overcomes the Survival Benefit Provided by HDAC-Based Induction Regimens in Mantle Cell Lymphoma: Data from a Real-Life and Long-Term Cohort.
de Pádua Covas Lage LA; Elias MDV; Reichert CO; Culler HF; de Freitas FA; de Oliveira Costa R; Rocha V; da Siqueira SAC; Pereira J
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835453
[TBL] [Abstract][Full Text] [Related]
33. Autologous hematopoietic cell transplantation of mantle cell lymphoma: emerging trends.
Falcone U; Kuruvilla J
Curr Opin Hematol; 2017 Nov; 24(6):502-508. PubMed ID: 28832354
[TBL] [Abstract][Full Text] [Related]
34. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.
Till BG; Gooley TA; Crawford N; Gopal AK; Maloney DG; Petersdorf SH; Pagel JM; Holmberg L; Bensinger W; Press OW
Leuk Lymphoma; 2008 Jun; 49(6):1062-73. PubMed ID: 18452065
[TBL] [Abstract][Full Text] [Related]
35. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang MI; Cohen JB; Calzada O; Churnetski MC; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast MA; Fenske TS; Narayana Rao Gari S; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns TF; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK
J Clin Oncol; 2019 Feb; 37(6):471-480. PubMed ID: 30615550
[TBL] [Abstract][Full Text] [Related]
36. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.
Chakhachiro ZI; Saliba RM; Okoroji GJ; Korbling M; Alousi AM; Betul O; Anderlini P; Ciurea SO; Popat U; Champlin R; Samuels BI; Medeiros LJ; Bueso-Ramos C; Khouri IF
Cancer; 2013 Sep; 119(18):3318-25. PubMed ID: 23775587
[TBL] [Abstract][Full Text] [Related]
37. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
[TBL] [Abstract][Full Text] [Related]
38. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024.
Ip A; Della Pia A; Goy AH
Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38493059
[TBL] [Abstract][Full Text] [Related]
39. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS; Barr PM; Phillips T; Leblanc M; Fisher RI; Cheson BD; Smith SM; Faham M; Wilkins J; Leonard JP; Kahl BS; Friedberg JW
Br J Haematol; 2017 Mar; 176(5):759-769. PubMed ID: 27992063
[TBL] [Abstract][Full Text] [Related]
40. First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma.
Bhella S; Varela NP; Aw A; Bredeson C; Cheung M; Crump M; Fraser G; Sajkowski S; Kouroukis T
Curr Oncol; 2020 Dec; 27(6):e632-e644. PubMed ID: 33380879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]